IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC
| dc.contributor.author | Barrios, C. H. | |
| dc.contributor.author | Spigel, D. | |
| dc.contributor.author | de Marinis, F. | |
| dc.contributor.author | Giaccone, G. | |
| dc.contributor.author | Reinmuth, N. | |
| dc.contributor.author | Vergnenegre, A. | |
| dc.contributor.author | Morise, M. | |
| dc.contributor.author | Felip, E. | |
| dc.contributor.author | Andric, Z. G. | |
| dc.contributor.author | Geater, S. | |
| dc.contributor.author | Mocci, S. | |
| dc.contributor.author | McCleland, M. | |
| dc.contributor.author | Enquist, I. | |
| dc.contributor.author | Komatsubara, K. M. | |
| dc.contributor.author | Deng, Y. | |
| dc.contributor.author | Kuriki, H. | |
| dc.contributor.author | Wen, X. | |
| dc.contributor.author | Jassem, J. | |
| dc.contributor.author | Herbst, R. S. | |
| dc.contributor.author | Ozguroglu, M. | |
| dc.date.accessioned | 2021-03-05T21:09:44Z | |
| dc.date.available | 2021-03-05T21:09:44Z | |
| dc.identifier.citation | Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z. G. , Geater S., et al., "IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC", 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.915 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_d798644e-bd92-4577-88b2-a9801deca3e6 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/142261 | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.title | IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC | |
| dc.type | Bildiri | |
| dc.contributor.department | Sarah Cannon Research Institute , , | |
| dc.identifier.volume | 30 | |
| dc.contributor.firstauthorID | 157508 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]